​

Bicycle Therapeutics (BCYC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

BCYC Stock Forecast

Bicycle Therapeutics (BCYC) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $34.00, with a high of $48.00 and a low of $26.00. This represents a 353.94% increase from the last price of $7.49.

$5 $14 $23 $32 $41 $50 High: $48 Avg: $34 Low: $26 Last Closed Price: $7.49

BCYC Stock Rating

Bicycle Therapeutics stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 17 Buy (94.44%), 1 Hold (5.56%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 18 1 17 0 Strong Sell Sell Hold Buy Strong Buy

BCYC Price Target Upside V Benchmarks

TypeNameUpside
StockBicycle Therapeutics353.94%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--4
Avg Price Target--$39.25
Last Closing Price$7.49$7.49$7.49
Upside/Downside--424.03%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25543--12
Mar, 25553--13
Feb, 25553--13
Jan, 25553--13
Dec, 24553--13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 18, 2024Reni BenjaminJMP Securities$26.00$15.3269.71%247.13%
Oct 24, 2024Jay OlsonOppenheimer$48.00$25.3289.57%540.85%
Oct 24, 2024Kalpit PatelB.Riley Financial$28.00$25.3210.58%273.83%
Sep 16, 2024Swayampakula RamakanthH.C. Wainwright$55.00$27.02103.55%634.31%
Oct 07, 2021Edward TenthoffPiper Sandler$76.00$48.6956.09%914.69%
Oct 07, 2021Anthony ButlerRoth Capital$65.00$48.6933.50%767.82%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 18, 2024JMP SecuritiesOutperformOutperformhold
Oct 31, 2024Leerink PartnersOutperformOutperformhold
Oct 24, 2024RBC CapitalMarket OutperformMarket Outperformhold
Oct 24, 2024H.C. WainwrightBuyBuyhold
Oct 24, 2024OppenheimerOutperformOutperformhold
Sep 16, 2024Cowen & Co.BuyBuyhold
Sep 16, 2024H.C. WainwrightBuyBuyhold
Sep 06, 2024RBC CapitalBuyBuyhold
Sep 05, 2024RBC CapitalOutperforminitialise
Aug 07, 2024OppenheimerBuyBuyhold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.66$-2.67$-3.80$-5.08$-0.29----
Avg Forecast$-2.28$-2.69$-3.84$-5.22$-3.02$-3.52$-4.10$-3.73$-1.84
High Forecast$-1.43$-1.69$-1.61$-4.49$-2.80$-2.98$-2.78$-1.02$-0.24
Low Forecast$-3.19$-3.78$-6.97$-6.16$-3.41$-4.14$-4.81$-5.65$-3.87
Surprise %16.67%-0.74%-1.04%-2.68%-90.40%----

Revenue Forecast

$0 $140M $280M $420M $560M $700M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.39M$11.70M$14.46M$26.98M$35.27M----
Avg Forecast$9.30M$13.41M$14.87M$30.09M$37.29M$31.85M$49.35M$133.43M$356.90M
High Forecast$12.18M$17.57M$24.17M$43.36M$44.40M$58.14M$49.72M$136.02M$658.47M
Low Forecast$6.63M$9.56M$8.23M$24.03M$33.79M$10.37M$48.98M$130.84M$117.45M
Surprise %11.76%-12.75%-2.73%-10.36%-5.40%----

Net Income Forecast

$-250M $-200M $-150M $-100M $-50M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-51.01M$-66.82M$-112.72M$-180.66M$-169.03M----
Avg Forecast$-80.97M$-95.74M$-136.75M$-180.66M$-110.60M$-126.59M$-135.00M$-118.76M$-65.60M
High Forecast$-50.76M$-60.02M$-57.33M$-159.82M$-99.68M$-105.92M$-98.95M$-36.45M$-8.38M
Low Forecast$-113.64M$-134.37M$-247.95M$-219.09M$-121.52M$-147.25M$-171.04M$-201.06M$-137.65M
Surprise %-37.00%-30.21%-17.57%-52.82%----

BCYC Forecast FAQ

Is Bicycle Therapeutics stock a buy?

Bicycle Therapeutics stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 17 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Bicycle Therapeutics is a favorable investment for most analysts.

What is Bicycle Therapeutics's price target?

Bicycle Therapeutics's price target, set by 18 Wall Street analysts, averages $34 over the next 12 months. The price target range spans from $26 at the low end to $48 at the high end, suggesting a potential 353.94% change from the previous closing price of $7.49.

How does Bicycle Therapeutics stock forecast compare to its benchmarks?

Bicycle Therapeutics's stock forecast shows a 353.94% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Bicycle Therapeutics over the past three months?

  • April 2025: 41.67% Strong Buy, 33.33% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 38.46% Strong Buy, 38.46% Buy, 23.08% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 38.46% Strong Buy, 38.46% Buy, 23.08% Hold, 0% Sell, 0% Strong Sell.

What is Bicycle Therapeutics’s EPS forecast?

Bicycle Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.52, marking a 1113.79% increase from the reported $-0.29 in 2024. Estimates for the following years are $-4.1 in 2026, $-3.73 in 2027, and $-1.84 in 2028.

What is Bicycle Therapeutics’s revenue forecast?

Bicycle Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $31.85M, reflecting a -9.70% decrease from the reported $35.28M in 2024. The forecast for 2026 is $49.35M, followed by $133.43M for 2027, and $356.9M for 2028.

What is Bicycle Therapeutics’s net income forecast?

Bicycle Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-127M, representing a -25.11% decrease from the reported $-169M in 2024. Projections indicate $-135M in 2026, $-119M in 2027, and $-65.597M in 2028.